Recombinate, a hemophilia A treatment, was recommended forapproval by the European Community's Committee forProprietary Medicinal Products.
This recombinant Factor VIII product is marketed by BaxterHealthCare Corp.'s Hyland Division and manufactured in bulkby Genetics Institute Inc. (NASDAQ:GENIZ).
An estimated one of out every 6,500 European males suffersfrom hemophilia, a bleeding disorder.
On Wednesday, Baxter announced that it will pay Rhone-Poulenc Rorer $105 million to settle a long-standing patentlawsuit concerning ultra-pure Factor VIII:C concentrates fortreating hemophilia.
(c) 1997 American Health Consultants. All rights reserved.